PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 2, 2026Apmis1 citationsOpen Access

Glycemic Variability and Diabetic Events in COVID‐19 Patients Treated with Dexamethasone

Glycemic Variability and Diabetic Events in Hospitalized Patients With COVID‐19 Treated With Dexamethasone: An Observational Cohort Study

View Full Paper
Ask AI
Bookmark
Share

Authors

CCClara Lundetoft ClausenTBThomas BryrupCLChristian Leo‐HansenCopenhagen University Hospital

Discussion

Loading...

Member takes

Overview

Observational cohort study reveals increased glycemic variability during dexamethasone treatment in diabetic populations, suggesting critical monitoring needs.

Key Points

  • This research aims to investigate the impact of dexamethasone on glycemic variability and diabetic events among hospitalized patients with COVID-19.
  • Conducted an observational cohort study across multiple centers with 530 adults.
  • Estimated glycemic variability based on baseline HbA1c in different glucose tolerance groups.
  • Analyzed glycemic events using linear mixed models and competing risks analysis adjusted for confounders.
  • Average plasma glucose increased in all groups post-treatment; known diabetes had the highest increase by 2.4 mmol/L.
  • Cumulative incidence of diabetic events was 98% in known diabetes and 67% in unknown diabetes.
  • Only prediabetes patients did not return to baseline plasma glucose levels after treatment.

Cite This Study

Clausen et al. (2026) studied this question.

synapsesocial.com/papers/6980ff37c1c9540dea811fb4https://doi.org/10.1111/apm.70155
View Full Paper
Ask AI
Bookmark
Share